The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status. OBJECTIVE: To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites. INTERVENTIONS: The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days. MAIN OUTCOMES AND MEASURES: The primary end point was a global rank score in which all patients, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days. Higher values indicate better health (stability). Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events. RESULTS: Among the 300 patients who were randomized (median age, 61 years [interquartile range {IQR}, 52-68 years]; 64 [21%] women; 178 [59%] with type 2 diabetes; median LVEF of 25% [IQR, 19%-33%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235 pg/mL]), 271 completed the study. Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P = .31). There were no significant between-group differences in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; hazard ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34%], respectively; hazard ratio, 1.30 [95% CI, 0.89-1.88]; P = .17) or for the exploratory secondary end points. Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences. The number of investigator-reported hyperglycemic events was 16 (10%) in the liraglutide group vs 27 (18%) in the placebo group and hypoglycemic events were infrequent (2 [1%] vs 4 [3%], respectively). CONCLUSIONS AND RELEVANCE: Among patients recently hospitalized with heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization clinical stability. These findings do not support the use of liraglutide in this clinical situation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01800968.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in earlier smaller studies with liraglutide in patients with HF with reduced left ventricular ejection fraction, the GLP-1RA was associated with increased incidence of serious cardiac events (rhythm disorders, worsening of HF)”
From Safety of Semaglutide (2021) · cites this paper as [102]
Experimental — accuracy not yet measuredIn the citing paper
“Vildagliptin, not tested in a CVOT, had no significant effect on LVEF but led to an increase in LV volumes in a small trial.551”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [551]
In the citing paper
“Vildagliptin, not tested in a CVOT, had no significant effect on LVEF but led to an increase in LV volumes in a small trial.551”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [551]
In the citing paper
“Furthermore, 2 small randomized clinical trials of liraglutide in patients with HF with reduced EF, 1 of which enrolled patients with recent HF hospitalization, suggested potential harm of liraglutide, although neither trial found statistically significant differences.36,37”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [36]
In the citing paper
“In a placebo-controlled FIGHT trial, of patients with HFrEF, with and without T2DM (41%), liraglutide was not associated with an improvement in the composite primary endpoint of death, rehospitalization and NT-proBNP change.181”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [181]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,651
Anand, I. S., Fisher, L. D., Chiang, Y., Latini, R., Masson, S., Maggioni, A. P., Glazer, R. D., Tognoni, G., & Cohn, J. N. (2003) · Circulation · doi:10.1161/01.cir.0000054164.99881.00 · Cited by 857
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 706
Kyhl, K., Lønborg, J., Hartmann, B., Kissow, H., Poulsen, S. S., Ali, H. H. E., Kjær, A., Dela, F., Engstrøm, T., & Treiman, M. (2017) · Peptides · doi:10.1016/j.peptides.2017.04.009 · Cited by 17
Long-acting glucagon-like peptide-1 receptor agonist—status December 2018
Holst, J. J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.09 · Cited by 18
Rivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 17
The immunology of diabetic cardiomyopathy
Song, M., Dai, H., Zhou, Q., & Meng, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1542208 · Cited by 18
Siddiqi, T. J., Khan, M. S., Waqas, S. A., Spall, H. G. C. V., Shapiro, M. D., Fonarow, G. C., Januzzi, J. L., Afzal, A. M., Pandey, A., Butler, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70048 · Cited by 18
González-Luis, A., Llinares-Arvelo, V., Martínez‐Alberto, C. E., Hernández-Carballo, C., Fernández, C. M., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf223 · Cited by 20
New Antidiabetes Medications and Their Cardiovascular and Renal Benefits
Ferro, E. G., Elshazly, M. B., & Bhatt, D. L. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.007 · Cited by 17
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01121-x · Cited by 22
A Plethora of GLP-1 Agonists: Decisions About What to Use and When
Samson, S. L., & Garber, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0823-6 · Cited by 18
Tougaard, R. S., Jorsal, A., Tarnow, L., Hansson, N. H., Kistorp, C., Schou, M., Nielsen, R. R., Flyvbjerg, A., Videbæk, L. M., Mølgaard, H., et al. (2020) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2020.1751873 · Cited by 18
the directors of the JCS, J., Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00471-5 · Cited by 16
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
Diabetic cardiomyopathy: a comprehensive review of diagnosis, management, and future directions
Balakrishnan, B., Divyashree, M. S., Nayak, V., & Hariharapura, R. C. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01986-0 · Cited by 20
Anguita, M. P., Bayés‐Genís, A., Cepeda, J. M., Cinza‐Sanjurjo, S., Cosín, J., Leiro, M. C., Egocheaga, I., Escobar, C., Faraudo, M., García-Pinilla, J. M., et al. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30016-9 · Cited by 16
The effects of antidiabetic agents on heart failure
Wijnen, M., Duschek, E. J. J., Boom, H., & van Vliet, M. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01579-2 · Cited by 17
Staszewsky, L., Baviera, M., Tettamanti, M., Colacioppo, P., Robusto, F., D'Ettorre, A., Lepore, V., Fortino, I., Bisceglia, L., Attolini, E., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002708 · Cited by 13
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 17
Cersosimo, A., Salerno, N., Sabatino, J., Scatteia, A., Bisaccia, G., Rosa, S. D., Dellegrottaglie, S., Bucciarelli‐Ducci, C., Torella, D., & Leo, I. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02181-7 · Cited by 17
Sharma, A., Cannon, C. P., White, W. B., Liu, Y., Bakris, G. L., Cushman, W. C., & Zannad, F. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007649 · Cited by 15
Cardiovascular Effects of Liraglutide
Mikhail, N. E. (2018) · Current Hypertension Reviews · doi:10.2174/1573402114666180507152620 · Cited by 16
Women and diabetes: preventing heart disease in a new era of therapies
Galati, G., Sabouret, P., Germanova, O., & Bhatt, D. L. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.22 · Cited by 15
Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
Packer, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf645 · Cited by 21
Cardiovascular disease leads to a new algorithm for diabetes treatment
Rodriguez, V., Weiss, M. C., WEINTRAUB, H. S., Goldberg, I. J., & Schwartzbard, A. Z. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.004 · Cited by 15
Packer, M. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1183 · Cited by 15
Clinical aspects of heart failure in individuals with diabetes
Bowes, C. D., Lien, L. F., & Butler, J. (2019) · Diabetologia · doi:10.1007/s00125-019-4958-2 · Cited by 15
Hardoňová, M., Šiarnik, P., Siváková, M., Sucha, B., Penesová, A., Rádiková, Ž., Havranová, A., Imrich, R., Vlček, M., Žitňanová, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311162 · Cited by 15
What is the evidence regarding the safety of new obesity pharmacotherapies
Vidal, J., Flores, L., Jiménez, A., Pané, A., & de Hollanda, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01488-5 · Cited by 15
Targeting autophagy in diabetic cardiomyopathy: From molecular mechanisms to pharmacotherapy
Li, J., Xie, Y., Zheng, S., He, H., Wang, Z., Li, X.-X., Jiao, S., Liu, D., Yang, F., Zhao, H., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116790 · Cited by 16
Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?
Neves, J. S., Zannad, F. M., Butler, J., Packer, M., & Ferreira, J. P. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.026 · Cited by 15
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 15
Sridhar, V. S., Dubrofsky, L., Boulet, J., & Cherney, D. Z. I. (2020) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2020-0100 · Cited by 16
Does Weight Loss Improve Clinical Outcomes in Overweight and Obese Patients with Heart Failure?
Tabucanon, T., Wilcox, J. D., & Tang, W. H. W. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01367-z · Cited by 16
Sharma, A., Greene, S. J., Vaduganathan, M., Fudim, M., Ambrosy, A. P., Sun, J., McNulty, S. E., Hernandez, A. F., Borlaug, B. A., Velazquez, E. J., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13348 · Cited by 15
Self-citationShou, X., Wang, Y., Duan, C., Yuan, G., Wei, N., Yang, Y., & Hu, Y. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101194 · Cited by 16
Redouane, B., Greene, S. J., Fudim, M., Vaduganathan, M., Ambrosy, A. P., Sun, J., DeVore, A. D., McNulty, S. E., Mentz, R. J., Hernandez, A. F., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006758 · Cited by 17
Self-citationIs the Way to Someone’s Heart Through Their Stomach?
Packer, M. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004551 · Cited by 15
Obesity and heart failure: exploring the cardiometabolic axis
Rayner, J. J., Abdesselam, I., Pan, J., Lewis, A., & Rider, O. J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf090 · Cited by 15
GLP-1 Receptor Agonists in Heart Failure
Rahmani, A. R., Dhaliwal, S., Pastena, P., Kazakov, E., Jayaseelan, K., & Kalogeropoulos, A. P. (2025) · Biomolecules · doi:10.3390/biom15101403 · Cited by 15
Monzo, L., Savarese, G., Müllens, W., Abdin, A., Bozkurt, B., Chioncel, O. D., Hadidi, S. E., Gorter, T. M., Inciardi, R. M., Petrie, M. C., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70082 · Cited by 16
Schernthaner, G., Lehmann, R., Prázný, M., Czupryniak, L., Ducena, K., Fasching, P., Janež, A., Karasik, A., Kempler, P., Martinka, E., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0622-7 · Cited by 14
Otowa‐Suematsu, N., Sakaguchi, K., Kaneko, A., Ito, J., Morita, Y., Miura, H., Yamada, T., So, A., Komada, H., Okada, Y., et al. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13608 · Cited by 14
Cardiorenal interactions in heart failure: insights from recent therapeutic advances
Damman, K., & Testani, J. M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad096 · Cited by 17
Treat Obesity to Treat Type 2 Diabetes Mellitus
Sulu, C., & Yumuk, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01536-3 · Cited by 20
Karlström, P., Pivodic, A., & Fu, M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.12.004 · Cited by 14
Martínez, J. J. G. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.03.005 · Cited by 15
Hamad, F., Elnour, A. A., Abdelgadir, E., Mohamed, S., Yousif, I., Don, J., Beshir, S. A., Amoodi, A. A., Fathelrahman, A. I., Sam, K. G., et al. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816999200821164129 · Cited by 14
Savarese, G., Schrage, B., Cosentino, F., Lund, L. H., Rosano, G. M. C., Seferovic, P. M., & Butler, J. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12937 · Cited by 14
Packer, M. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1093 · Cited by 14
Revisiting the Diabetes-Heart Failure Connection
Wallner, M., Eaton, D., von Lewinski, D., & Sourij, H. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1116-z · Cited by 14
Updates in Heart Failure: What Last Year Brought to Us
Dinatolo, E., Sciatti, E., Anker, M. S., Lombardi, C., Dasseni, N., & Metra, M. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12385 · Cited by 13
Alobaid, S. M., Alshahrani, R. M., Alonazi, A. S., Alrasheed, N. M., Alamin, M. A., Alshammari, T. K., Bin Dayel, A. F., Elnagar, D. M., Alotaibi, R. R., Almuthnabi, L. A., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17030374 · Cited by 13
Hegedűs, Z. I., Jakab, M. E., Gergely, T. G., Sayour, N. V., Kovács, A., Antal, S., Kovács, T., Ferdinándy, P., Varga, Z. V., & Tóth, V. É. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02806-5 · Cited by 16
Heart failure and obesity: novel insights leading to new treatment paradigms
Meems, L. M. G., van Veldhuisen, D. J., Sattar, N. A., & Lee, M. M. Y. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01190-7 · Cited by 16
Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
Rutledge, C. A., Enriquez, A., Redding, K., Lopez, M. A., Mullett, S. J., Gelhaus, S. L., Jurczak, M. J., Goetzman, E. S., & Kaufman, B. A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07482-9 · Cited by 13
Obesity, Challenges, and Weight-Loss Strategies for Patients With Ventricular Assist Devices
daSilva‐deAbreu, A., Rodgers, J. E., Seltz, J., Mandras, S. A., Lavie, C. J., Loro-Ferrer, J. F., Ventura, H. O., Schauer, P. R., & Vest, A. R. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.006 · Cited by 14
Qi, Z., Wu, D., Yan, Z., Wang, Q., Li, Y., Zhao, J., & Xu, F. (2025) · Obesity Reviews · doi:10.1111/obr.13912 · Cited by 14
Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes
BAJAJ, H. S., Aljabri, B. A., & Verma, S. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000562 · Cited by 13
Lee, K., Noh, J. H., Park, S., Choi, K. M., Kang, S., Won, K. C., Cho, H., Moon, M. K., & Korean Society of Heart Failure (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0420 · Cited by 13
Tracking Pathways Linking Obesity with Heart Failure
Manta, E., Iliakis, P., Fragoulis, C., Leontsinis, I., Stamoulopoulos, I., Chrysohoou, C. A., & Tsioufis, K. P. (2025) · Nutrients · doi:10.3390/nu17071250 · Cited by 17
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Михайловна, Г. Е., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-3-6-76 · Cited by 12
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 13
Semaglutide and heart failure: Updated meta-analysis.
Barbagelata, L., Masson, W. M., Lobo, M., & Bluro, I. M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102721 · Cited by 13
Cardiovascular Outcome Trials of the Incretin-Based Therapies: What Do We Know So Far?
Mora, P. F., & Johnson, E. L. (2016) · Endocrine Practice · doi:10.4158/ep161481.ra · Cited by 12
McHugh, K. R., DeVore, A. D., Mentz, R. J., Edmonston, D. L., Green, J. B., & Hernandez, A. F. (2018) · Clinical Cardiology · doi:10.1002/clc.23054 · Cited by 12
Self-citationSchroeder, M., & Laustsen, C. (2016) · Bioscience Reports · doi:10.1042/bsr20160186 · Cited by 12
Diabetes medications and cardiovascular disease: at long last progress
Lupsa, B. C., & Inzucchi, S. E. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000400 · Cited by 12
Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis
Kobalava, Z. D., Yeshniyazov, N. V., Medovchshikov, V., & Хасанова, Э. Р. (2019) · Kardiologiia · doi:10.18087/cardio.2019.4.10253 · Cited by 15
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Athyros, V. G., Doumas, M. N., & Karagiannis, A. I. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190426162746 · Cited by 13
Yamamoto, M., Seo, Y., Ishizu, T., Nishi, I., Hamada‐Harimura, Y., Machino‐Ohtsuka, T., Sato, K., Sai, S., Sugano, A., Obara, K., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0240 · Cited by 12
Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”
Manolis, A. S., Manolis, T. A., & Manolis, A. S. (2018) · Drugs · doi:10.1007/s40265-018-0985-4 · Cited by 12
Cavallari, I., Maddaloni, E., Pieralice, S., Mulè, M. T., Buzzetti, R., Ussia, G. P., Pozzilli, P., & Grigioni, F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa427 · Cited by 12
Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists
Llinares-Arvelo, V., Martínez‐Alberto, C. E., González-Luis, A., Macía-Heras, M., Siverio-Morales, O., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168096 · Cited by 14
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 13
Harrington, J., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Lingvay, I., Pagidipati, N. J., Sattar, N. A., Spall, H. G. C. V., Verma, S., & McGuire, D. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-023-02016-z · Cited by 11
Self-citationAnti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Harrington, J., Gale, S. E., & Vest, A. R. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011518 · Cited by 11
Wang, T., Yang, Q., Cheng, X.-Y., Ding, J.-C., & Hu, P.-F. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10438-2 · Cited by 12
Mahapatro, A., Bozorgi, A., Obulareddy, S. U. J., Jain, S. M., Korsapati, R. R., Kumar, A., Patel, K., Moghadam, S. S., Arya, A., Alotaibi, A. J., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002592 · Cited by 12
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 15
Diabetes mellitus and heart failure: an update on pathophysiology and therapy
Potere, N., BUONO, M. G. D., Vecchié, A., Porreca, E., ABBATE, A., DENTALI, F., & Bonaventura, A. (2022) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.22.05967-1 · Cited by 11
Banerjee, M., Maisnam, I., & Mukhopadhyay, S. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07432-5 · Cited by 11
Targeting G protein‐coupled receptors for heart failure treatment
Thai, B. S., Chia, L. Y., Nguyen, A. T. N., Qin, C. X., Ritchie, R. H., Hutchinson, D. S., Kompa, A. R., White, P. J., & May, L. T. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16099 · Cited by 12
Wu, M., Ying, W., Chen, W., Kaizu, X., Song, M., & Lin, L. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10338-x · Cited by 13
Managing Obesity in Heart Failure
Harrington, J., Felker, G. M., Lingvay, I., Pagidipati, N. J., Pandey, A., & McGuire, D. K. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.09.005 · Cited by 11
Self-citationClinical impact of oral antidiabetic medications in heart failure patients
Palazzuoli, A., Ceccarelli, E., Ruocco, G. M., & Nuti, R. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9669-0 · Cited by 11
Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets.
Cong, S., Ramachandra, C. J. A., Ja, K. P. M. M., Yap, J., SHIM, W. S. N., Wei, L., & Hausenloy, D. J. (2020) · PubMed · Cited by 13
New and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 14
Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
Turkistani, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1535134 · Cited by 10
Khalil, I., Islam, M. R., Kamrul-Hasan, A. B. M., Nagendra, L., Promi, S. A., Sayed, M. A., Rahman, M. A., Sultana, N., Tasmi, N. A., Das, M., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.005 · Cited by 12
Role of GLP‐1 Receptor Agonists in Managing Cancer Therapy–Related Cardiac Dysfunction
Vignarajah, A., Kim, S., Albliwi, M., Ahn, H. M., Izda, A., Naffa, F., Vigneswaramoorthy, N. A., Barot, S. V., & Shah, G. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.040919 · Cited by 10
Caraballo, C., Khera, R., Jones, P. G., Decker, C., Schulz, W. L., Spertus, J. A., & Krumholz, H. M. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.006231 · Cited by 10
Cardiovascular effects of antiobesity drugs: are the new medicines all the same?
Cataldi, M., Cignarelli, A., Giallauria, F., Muscogiuri, G., Barrea, L., Savastano, S., & Colao, A. A. L. (2020) · International Journal of Obesity Supplements · doi:10.1038/s41367-020-0015-3 · Cited by 11
Die Biomarker BNP und NT‑proBNP
Oremek, G. M., Passek, K., Holzgreve, F., von der Eltz, V., & Dröge, J. (2023) · Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie · doi:10.1007/s40664-022-00491-9 · Cited by 10
Nieminen, M. S., Fonseca, C., Brito, D. A., & Wikström, G. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux003 · Cited by 9
Feasibility of Serial 6-min Walk Tests in Patients with Acute Heart Failure
Collins, S. P., Thorn, M. D., Nowak, R. M., Levy, P. D., Fermann, G. J., Hiestand, B. C., Cowart, T. D., Venuti, R. P., Hiatt, W. R., Foo, S., et al. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6090084 · Cited by 10
Positioning Metabolism as a Central Player in the Diabetic Heart
Mereweather, L. J., Aparicio, C. N. M., & Heather, L. C. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.1.92 · Cited by 11
Palee, S., Chattipakorn, S. C., & Chattipakorn, N. (2017) · Physiological Research · doi:10.33549/physiolres.933558 · Cited by 11
Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
Siasos, G., Bletsa, E., Stampouloglou, P. K., Paschou, S. Α., Oikonomou, E. K., Tsigkou, V., Antonopoulos, A. S., Vavuranakis, M., & Tousoulis, D. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201109110107 · Cited by 10
Hsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 11
Chronic Heart Failure and Diabetes Mellitus: Pathogenesis and Possibilities of Treatment
Обрезан, А. Г., & Куликов, Н. В. (2018) · Kardiologiia · doi:10.18087/cardio.2018.7.10156 · Cited by 10
Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients
Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 10
Metadata
- Authors
- Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., McNulty, S. E., Anstrom, K. J., Shah, M. R., Braunwald, E., Cappola, T. P., & for the NHLBI Heart Failure Clinical Research Network
- Affiliations
- University of Pennsylvania (US)
- Duke University (US)
- Mayo Clinic (US)
- Brigham and Women's Hospital (US)
- University Hospitals of Cleveland (US)
- Emory University (US)
- Washington University in St. Louis (US)
- Thomas Jefferson University (US)
- Tufts University (US)
- National Heart, Lung, and Blood Institute (US)
- Brigham and Women’s Hospital, Boston, Massachusetts
- Corresponding author
- Margulies, Kenneth B.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-08-02
- Volume
- 316
- Issue
- 5
- Pages
- 500
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5021525
- OpenAlex
- W2505843168
- Cited by
- 706
- References
- 24
- Citations by year
- 2026: 85 · 2025: 99 · 2024: 75 · 2023: 58 · 2022: 46 · 2021: 50 · 2020: 77 · 2019: 68 · 2018: 78 · 2017: 56 · 2016: 13
- FWCI
- 59.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U10HL110297, U10HL110342, U10HL084904, U10HL110262, U01HL084861, U10HL110309, U10HL110336, U10HL110302, U10HL110337, U10HL110312, U10HL110338)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- liraglutide, GLP-1 receptor agonists, advanced heart failure, reduced left ventricular ejection fraction, clinical stability, heart failure readmission, mortality, NT-proBNP, myocardial metabolism, type 2 diabetes, cardiac structure and function, 6-minute walk distance, quality of life, subcutaneous injection, cardioprotection
- MeSH terms
- Liraglutide, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Middle Aged, Patient Readmission, Quality of Life, Stroke Volume, United States, Odds Ratio, Treatment Outcome, Ventricular Dysfunction, Left, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
